(Q24244979)

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

A double-blind trial of feprazone in osteoarthritis of the hip

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

A multicenter trial of sulindac in osteoarthritis of the hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

A double-blind comparative study of 150 mg flurbiprofen daily and 75 mg indomethacin daily in the treatment of osteoarthrosis of the hip joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

‘Osmosin’ in general practice: preliminary report of a double-blind study in the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

A Double-Blind Comparison of Naproxen with Indomethacin in Osteoarthrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

Nonsteroidal antiinflammatory drugs and aspirin--analyzing the scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

Variations in responses to non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

Measuring health status in arthritis. The arthritis impact measurement scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Diacerhein in the treatment of osteoarthritis of the hip

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Guidelines for the medical management of osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Piroxicam and naproxen in patients with osteoarthritis of the hip waiting for total hip replacement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Piroxicam and indomethacin suppositories for painful coxarthrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Double-blind comparison of flurbiprofen and sulindac for the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Indices of severity and disease activity for osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose cross-over comparison for coxarthrosis pain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Variance imputation for overviews of clinical trials with continuous response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

The art and science of nonsteroidal anti-inflammatory drug selection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Nonsteroidal antiinflammatory drugs--differences and similarities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Ibuprofen in the management of osteoarthrosis of the hip

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Ketoprofen in the management of osteoarthrosis of the hip: comparison with phenylbutazone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Sulindac in osteoarthrosis of the hip

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Double-blind cross-over study of ketoprofen and phenylbutazone in patients with chronic osteoarthrosis of the hip

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Assessment outcomes of clinical drug trials in osteoarthritis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Naproxen in osteoarthrosis. Double-blind crossover trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Four new anti-inflammatory drugs: responses and variations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Variability in response to NSAIDs. Fact or fiction?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

A Double-Blind Multicentre Comparison of Diclofenac Sodium and Naproxen in Osteoarthrosis of the Hip

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000517.PUB2

7 January 2021